| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2136812 | Leukemia Research | 2013 | 5 Pages |
Abstract
We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eyal C. Attar, Philip C. Amrein, James W. Fraser, Amir T. Fathi, Steven McAfee, Martha Wadleigh, Daniel J. DeAngelo, David P. Steensma, Richard M. Stone, Julia Foster, Donna Neuberg, Karen K. Ballen,